Can Belzutifan Improve Adjuvant Therapy? - Top-Institutions - MDSpire

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.

  • By

  • Kathryn Wighton

  • July 8, 2026

  • 4 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Oncology

  • #3

    Vanderbilt University Medical Center
    Vanderbilt University Medical Center

    Nashville, TN

    Key Differentiators

    • Oncology

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

  • #5

    University of Milan
    University of Milan

    Milan, Italy

    Key Differentiators

    • Oncology

Original Source(s)

Can Belzutifan Improve Adjuvant Therapy?

  • by Kathryn Wighton

  • July 8, 2026

Related Content

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

FDA Approves Expanded Liquid Biopsy Panel

Updated liquid biopsy combines genomic and epigenomic profiling for companion diagnostic use across multiple tumor types.

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.